Certara (NASDAQ:CERT) Updates FY 2022 Earnings Guidance

Certara (NASDAQ:CERTGet Rating) issued an update on its FY 2022 earnings guidance on Monday morning. The company provided earnings per share guidance of $0.48-$0.53 for the period, compared to the consensus earnings per share estimate of $0.44. The company issued revenue guidance of $350.00 million-$360.00 million, compared to the consensus revenue estimate of $355.92 million.

Certara stock traded down $1.00 on Monday, hitting $18.15. The company’s stock had a trading volume of 7,674 shares, compared to its average volume of 646,908. The firm has a market cap of $2.90 billion, a P/E ratio of -228.38, a price-to-earnings-growth ratio of 0.74 and a beta of 1.55. The company has a quick ratio of 2.98, a current ratio of 2.98 and a debt-to-equity ratio of 0.28. The company has a fifty day moving average price of $20.57 and a 200-day moving average price of $26.52. Certara has a one year low of $17.70 and a one year high of $45.48.

Certara (NASDAQ:CERTGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported $0.11 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.11. Certara had a negative net margin of 4.02% and a positive return on equity of 3.65%. The firm had revenue of $81.60 million for the quarter, compared to analyst estimates of $79.88 million. During the same quarter in the previous year, the firm posted $0.06 EPS. The business’s revenue for the quarter was up 22.3% on a year-over-year basis. Analysts anticipate that Certara will post 0.5 EPS for the current year.

Several research firms have recently weighed in on CERT. Morgan Stanley lowered their target price on shares of Certara from $27.00 to $25.00 and set an equal weight rating on the stock in a report on Thursday, March 3rd. Barclays reduced their price target on shares of Certara from $48.00 to $26.00 and set an overweight rating on the stock in a research report on Thursday, March 3rd. Jefferies Financial Group upgraded shares of Certara from a hold rating to a buy rating and set a $31.00 price target on the stock in a research report on Tuesday, January 11th. Finally, Zacks Investment Research downgraded shares of Certara from a buy rating to a hold rating in a research report on Tuesday, February 15th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of Buy and an average target price of $31.00.

In related news, Director Mason P. Slaine sold 125,000 shares of the stock in a transaction that occurred on Wednesday, March 16th. The stock was sold at an average price of $20.17, for a total transaction of $2,521,250.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO William F. Feehery sold 90,000 shares of the stock in a transaction that occurred on Thursday, February 17th. The stock was sold at an average price of $24.32, for a total value of $2,188,800.00. The disclosure for this sale can be found here. Insiders sold a total of 221,352 shares of company stock worth $4,844,766 over the last quarter. 4.02% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. grew its stake in shares of Certara by 12.8% during the 4th quarter. BlackRock Inc. now owns 6,466,287 shares of the company’s stock worth $183,771,000 after acquiring an additional 733,317 shares in the last quarter. State Street Corp grew its stake in shares of Certara by 46.9% during the 4th quarter. State Street Corp now owns 1,429,795 shares of the company’s stock worth $40,635,000 after acquiring an additional 456,213 shares in the last quarter. Morgan Stanley grew its stake in shares of Certara by 6,519.8% during the 2nd quarter. Morgan Stanley now owns 418,242 shares of the company’s stock worth $11,848,000 after acquiring an additional 411,924 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Certara by 138.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 285,819 shares of the company’s stock worth $9,462,000 after acquiring an additional 165,844 shares in the last quarter. Finally, Stifel Financial Corp grew its stake in shares of Certara by 1,465.3% during the 4th quarter. Stifel Financial Corp now owns 148,785 shares of the company’s stock worth $4,229,000 after acquiring an additional 139,280 shares in the last quarter. 52.08% of the stock is owned by institutional investors and hedge funds.

About Certara (Get Rating)

Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.

See Also

Earnings History and Estimates for Certara (NASDAQ:CERT)

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.